In a recent development concerning governmental regulations surrounding telemedicine, the United States Drug Enforcement Administration (DEA) has indicated its intent to contemplate a potential new Special Registration for telemedicine. The goal of this registration process would be to allow health professionals the ability to prescribe controlled substances to their patients without the necessity of an in-person examination.
The DEA signaled this consideration on August 4, 2023, when it filed a pre-publication Notice of Meeting. This document was then published in the Federal Register on August 7th. As stated in the notice, the DEA plans to conduct several comprehensive public listening sessions throughout the fall. Aimed at understanding all angles, these public discussions are designed to provide a platform for parties interested in the matter to express and debate their views.
For more detailed information on this emerging situation, you can review the DEA’s preliminary Notice of Meeting and other related materials on its official website or via other reliable news outlets. Particularly, this article from JDSupra provides a comprehensive examination of the issue.
This development is expected to generate waves of discussion within the legal and medical communities as the proposal, if enacted, will significantly affect telemedicine practices and regulations. It can present both opportunities and challenges and thus legal practitioners, as well as stakeholders in the medical industry, will need to pay close attention.
The public listening sessions to be conducted by the DEA will indeed be a crucial platform for communicating diverse opinions, concerns and suggestions for professionals from various sectors. Participation and observation in these sessions are highly encouraged for those looking to understand, influence or adapt to these changes as they unfold.